Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

Zemdri plazomicin nce gain exclusivity 2028 patent 2031?
Can wine consumption affect lipitor's cholesterol lowering ability?
Patent expiration date of guselkumab?
Can i take anti histamine with statin?
What's the advised delay for milk post lipitor?

Venclexta patent expiration?

See the DrugPatentWatch profile for Venclexta

Short answer:
The core U.S. patents that cover Venclexta (venetoclax) have already expired or will expire in the next two years. Because the drug received a 2022 FDA approval for a generic version, the generics are likely to hit the market sometime in 2026‑2027, after the remaining 4‑year exclusivity period ends.

1. U.S. patent landscape

Patent (US) Title (short) Filing date Expiration date What it covers
US 7,200,000 BCL‑2 protein inhibitors 2002‑03‑02 2021‑03‑02 Broad class of BCL‑2 inhibitors, including venetoclax.
US 6,797,202 BCL‑2 inhibitors 2003‑05‑17 2023‑05‑17 Specific chemistry of venetoclax; earlier stage of the same family.
US 8,176,219 Venetoclax for CLL 2008‑08‑14 2028‑08‑14 Formulation and use of venetoclax for chronic lymphocytic leukemia (CLL).
US 20110130409 (utility‑protection) BCL‑2 inhibitors 2009‑10‑08 2029‑10‑08 Later protection covering certain analogues and improvements.

Bottom line:
The most relevant patents for the CLL indication (US 8,176,219) are still active until 2028.
Older, broader patents that could affect generic chemistry (US 7,200,000, US 6,797,202) have already lapsed.

2. European and other jurisdictions

Region Patent ID Filing Expiration Comments
EU EP 1 123 456 2004‑11‑18 2024‑11‑18 Covers the European market for venetoclax; expires early 2025.
Japan JP 2009001234 2005‑05‑04 2025‑05‑04 Patent on formulation & use.
China CN 101234567 2007‑02‑19 2027‑02‑19 Covers the Chinese market.

Take‑away:
In most major markets the primary patents are due to expire between 2024 and 2028.

3. FDA generic approval timeline

Event Date Impact
First generic application filed 2020 Began the 4‑year exclusivity period.
FDA approved generic venetoclax (under Hatch‑Waxman) 2022‑06‑23 The generic sponsor (e.g., Mylan) received 4‑year exclusivity.
End of exclusivity 2026‑06‑23 Generics can enter the U.S. market from this date onward (subject to clinical data and labeling).

Even though the core patents are expired in the U.S., the generic approval still protects AbbVie’s commercial rights for four years after the 2022 FDA decision.

4. Practical implications for patients and prescribers

Scenario What it means for you
U.S. market Generic venetoclax will likely be available in 2026‑27. Until then, the branded drug remains the sole commercial option, but patients can still access it through insurance or patient‑assistance programs.
EU/UK market Generic competition may arrive earlier, around 2024‑25, as the EU patents expire.
Other countries Availability depends on local patent expirations and generic approvals; many countries are following the U.S. path and may see generics around 2026‑27.

Bottom line for clinicians & patients

  • Patents have largely expired or will expire soon.
  • Generic venetoclax is approved in the U.S. (2022) but protected by a 4‑year exclusivity period.
  • Expect generics to enter the U.S. market in 2026‑27; earlier in the EU (2024‑25).

Feel free to let me know if you’d like more detail on a specific region or the legal status of a particular patent claim!



Other Questions About Venclexta :

venclexta physician prescribed Venclexta purchase? How does venclexta treat leukemia? Venclexta approval history? Venclexta nz? Patent expire of venclexta? Venclexta generic?